GlassScriptPhysician profile
Crystal Harris
NPI 1144634486
$2,008.33
in general payments reported to CMS, 2019-2025
17 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2023: $178 · 2024: $474 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.52 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $455.09 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $406.73 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $317.55 | 2024-2025 | Auvelity |
| Alkermes, INC. | $152.78 | 2025 | Lybalvi, Aristada |
| Glaxosmithkline, LLC. | $120.50 | 2023 | Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $116.23 | 2023-2025 | Spravato |
| Mannkind Corporation | $108.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $90.37 | 2024 | Austedo Xr |
| Boston Scientific Corporation | $55.61 | 2023-2024 | Ams 700, Solyx Sis System |
| Tris Pharma INC | $43.40 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $29.49 | 2025 | Cobenfy |
| Pacira Pharmaceuticals Incorporated | $20.98 | 2021 | |
| Abbvie INC. | $20.86 | 2025 | |
| Neurocrine Biosciences, INC. | $20.53 | 2025 | |
| Noven Therapeutics, LLC | $18.84 | 2025 | Xelstrym |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.00 | 2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $13.60 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.